Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fresenius Kabi Launches Levofloxacin Freeflex IV | Contract Pharma
Breaking News

Fresenius Kabi Launches Levofloxacin Freeflex IV

Designed for easier handling with enhanced safety

Fresenius Kabi USA has launched Levofloxacin in 5% Dextrose Injection in freeflex containers. Freeflex is designed for infusion solutions and has been marketed globally since 2005. Freeflex has multilayer polyolefin film that is PVC-free, plasticizer-free, non-DEHP, and is designed for easier handling with enhanced safety, and environmental performance.
 
Levofloxacin is a fluoroquinolone antibacterial indicated for use in the treatment of bacterial infections caused by susceptible bacteria, including pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis and anthrax.
 
“The introduction of Levofloxacin using the freeflex technology expands our market leading anti-infective business with a ready to use formulation and provides customers with a new choice in serving their patients,” said John Ducker, president and chief executive officer of Fresenius Kabi USA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters